Japanese pharmaceutical company Astellas Pharma Inc (TSE: 4503) announced on Thursday that its US subsidiary iota Biosciences Inc has received approval from the US Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) for an Early Feasibility Study (EFS).
The EFS is intended to assess the safety and feasibility of an investigational implantable device designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals affected by underactive bladder (UAB).
The FDA has offered a staged approval of the EFS for this novel device. The first stage includes enrolment of three subjects (at least one male and one female). Following successful safety results from Stage 1, the study will be expanded to a total of 10 subjects.
Michel Maharbiz, Ph.D., iota Biosciences' CEO, said: "Current treatment options for underactive bladder are limited, often forcing patients to rely on clean intermittent catheterisation, which can be burdensome and carry risk of complications. Our team has diligently worked on a potential alternative treatment option, achieving concept to IDE approval in less than four years, a remarkable feat that highlights our commitment to patients and innovation. We are excited to advance clinical development and bring this potential new solution closer to those in need."
Pfizer's Hympavzi (marstacimab-hncq) receives US FDA approval for Hemophilia A or B treatment
Capricor begins BLA submission for deramiocel in Duchenne muscular dystrophy
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Biogen receives FDA Breakthrough Therapy Designation for felzartamab
Inspira Technologies develops new disposable kit for perfusion market
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Teva's Prolia biosimilar candidate accepted for review by FDA and EMA
Boehringer receives Breakthrough Therapy designation for survodutide
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices